Trials / Recruiting
RecruitingNCT06926634
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanzalintinib | Provided by Exelixis |
Timeline
- Start date
- 2025-12-09
- Primary completion
- 2034-12-31
- Completion
- 2034-12-31
- First posted
- 2025-04-14
- Last updated
- 2025-12-17
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06926634. Inclusion in this directory is not an endorsement.